Alnylam Pharmaceuticals (NASDAQ:ALNY) Given Neutral Rating at Cantor Fitzgerald
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report)‘s stock had its “neutral” rating restated by equities researchers at Cantor Fitzgerald in a report released on Tuesday, Benzinga reports. They presently have a $165.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 6.63% from the stock’s previous close. […]
More Stories
Analyzing Jin Medical International (NASDAQ:ZJYL) and Predictive Oncology (NASDAQ:POAI)
Predictive Oncology (NASDAQ:POAI – Get Free Report) and Jin Medical International (NASDAQ:ZJYL – Get Free Report) are both small-cap medical...
TFI International (OTCMKTS:TFIFF) Trading Up 1.7% – Should You Buy?
TFI International Inc (OTCMKTS:TFIFF – Get Free Report)’s share price was up 1.7% during trading on Tuesday . The company...
TP ICAP Group (LON:TCAP) Stock Price Down 1.3% – Here’s What Happened
TP ICAP Group PLC (LON:TCAP – Get Free Report) dropped 1.3% on Tuesday . The company traded as low as...
SANUWAVE Health (OTCMKTS:SNWV) Trading Up 2.1% – Still a Buy?
SANUWAVE Health, Inc. (OTCMKTS:SNWV – Get Free Report)’s stock price rose 2.1% during trading on Tuesday . The company traded...
ProSiebenSat.1 Media (ETR:PSM) Shares Down 0.4% – Time to Sell?
Shares of ProSiebenSat.1 Media SE (ETR:PSM – Get Free Report) traded down 0.4% on Tuesday . The stock traded as...
LEG Immobilien (FRA:LEG) Shares Down 1.3% – What’s Next?
Shares of LEG Immobilien SE (FRA:LEG – Get Free Report) were down 1.3% during mid-day trading on Tuesday . The...